USAC:NYSEUSA Compression Partners, LP Analysis
Data as of 2026-06-13 - not real-time
$26.73
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
USA Compression Partners posted a robust 35% year‑over‑year revenue increase to $1.08 billion and lifted Q1 EPS to $0.27, beating the Zacks consensus revenue estimate by 13% while marginally missing the EPS forecast. Operating margins remain healthy at 28.6% and free cash flow is solid at $255 million, supporting its generous 7.86% dividend yield. However, the dividend payout ratio sits above 200%, raising concerns about dividend sustainability given the company’s minimal cash balance ($14.5 million) and a staggering debt‑to‑equity ratio of 945. Technical indicators show a bullish SMA alignment (20‑day > 50‑day > 200‑day) but a bearish MACD and an RSI of 39, indicating the stock is near oversold conditions at $26.73, just above the $26.01 support level. The market’s “Extreme Greed” sentiment (fear‑greed index 89.86) and a modest upside of ~11% to the DCF‑derived fair value of $43 suggest room for price appreciation, yet the high 30‑day volatility (38%) and low beta (0.32) highlight a volatile but low‑beta profile. Overall, the stock presents a mixed picture: strong top‑line growth and cash generation counterbalanced by excessive leverage and an unsustainable dividend policy.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above key support at $26.01
- High dividend yield but payout >200% suggests risk
- Mixed technical signals (bullish SMA, bearish MACD, low RSI)
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue growth of 35% YoY and improving forward PE to 14.95
- DCF fair value indicates ~11% upside and analyst median target $29.5
- Strong operating cash flow and free cash flow generation
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Extremely high leverage (debt‑to‑equity 945) poses balance‑sheet risk
- Energy equipment sector cyclicality and regulatory exposure
- Unsustainable dividend policy may force future payout reductions
Key Metrics & Analysis
Financial Health
Revenue Growth35.10%
Profit Margin11.91%
P/E Ratio27.3
ROE84.75%
ROA6.65%
Debt/Equity945.48
P/B Ratio-30.1
Op. Cash Flow$425.7M
Free Cash Flow$255.5M
Industry P/E21.5
Technical Analysis
TrendBullish
RSI39.5
Support$26.01
Resistance$30.55
MA 20$28.58
MA 50$27.91
MA 200$25.57
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value$43.32
Target Price$29.67
Upside/Downside10.99%
GradeFair
TypeGrowth
Dividend Yield7.86%
Risk Assessment
Beta0.32
Volatility38.35%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.